BPC-157 + TB-500 (Wolverine Stack)

BPC-157 + Ac-LKKTETQ two-peptide research pairing · no established biological synergy

Component-specific identity, chromatographic purity and quantitative content; a single blended purity value is insufficient · target, verify batch COACAS 137525-51-0RUO

Research statusNo controlled evidence for the marketed combination; component evidence is predominantly preclinical reference context · supplied material is RUO

Supplied formTwo-component peptide material: linear BPC-157 15-mer plus N-acetylated TB-500 7-mer fragment

Lead time14–21 days

BPC-157 + TB-500 (Wolverine Stack) — Lot- and presentation-specific lyophilized research material; confirm whether components are separate or co-presented and verify the released appearance for each

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research applications include component-specific analytical qualification, controlled comparison of two preclinical repair-pathway hypotheses and development of methods that resolve both peptides in one matrix
The pairing is useful only when the experimental design includes each component alone, vehicle controls and a prespecified interaction analysis.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 137525-51-0
Formula: Confirm supplied form on batch COA
Molecular weight: approximately 1,419.5 Da
Appearance: Lot- and presentation-specific lyophilized research material; confirm whether components are separate or co-presented and verify the released appearance for each
Purity: Component-specific identity, chromatographic purity and quantitative content; a single blended purity value is insufficient · target, verify batch COA
Storage: Use only the released-lot COA, SDS and stability statement for the actual presentation. If separate, qualify each component independently; if co-presented, require mixture-specific stability, compatibility, concentration, matrix, container and hold-time evidence. Do not apply a generic 2–8°C or 30-day rule.
MOQ: On request
Lead time: 14–21 days

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about BPC-157 + TB-500 (Wolverine Stack)

This catalogue name refers to BPC-157, the linear 15-mer GEPPPGKPADDAGLV, paired with TB-500 as the N-acetylated 7-mer fragment Ac-LKKTETQ. The fragment is chemically distinct from full-length 43-residue thymosin β4/timbetasin. Separate preclinical findings do not establish the performance of a co-presented material. The 2021 retrospective knee report contacted 16 of 17 patients and included only four recipients of BPC-157 plus material described as thymosin beta-4/TB4; it did not establish that material as sequence-resolved Ac-LKKTETQ and was uncontrolled. It therefore does not prove efficacy, compatibility or synergy for this catalogue pairing. Exact physical presentation must be confirmed per quote and released lot.

Component-level identity and assay development, controlled in-vitro pathway comparisons, cell-migration or matrix-remodelling hypotheses, and mixture-specific analytical/stability research
These are laboratory applications, not treatment indications.

Mechanism context

The question the literature is testing

BPC-157 literature proposes effects involving nitric-oxide signalling, endothelial pathways and growth-factor expression. TB-500 is an N-acetylated actin-binding fragment whose rationale is substantially extrapolated from full-length thymosin β4. Complementary mechanisms are a hypothesis, not demonstrated synergy. Component identity, concentration, ratio, matrix and orthogonal controls must be defined directly.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaRepair and regenerative research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary use
Neither separate preclinical findings nor a small uncontrolled retrospective report establishes safety of the combination
Chemical purity does not establish sterility, bacterial-endotoxin control, injectable suitability or clinical compatibility
BPC-157 is prohibited under WADA S0 and TB-500/thymosin-β4 derivatives under WADA S2
Follow each component SDS and institutional controls.

Interactions reported in the literature

No validated drug-interaction or combination-safety data exist for this pairing
Vendor “synergy,” stacking, anticoagulant, chemotherapy and other patient-medication lists are not controlled evidence and are not provided as clinical guidance.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

BPC-157 + TB-500 (Wolverine Stack) factory batch COAs

BPC-157 + TB-500 (Wolverine Stack) 10 mg Factory batch COA protected preview

BPC-157 + TB-500 (Wolverine Stack)10 mg · WHJLP-BB10-260330-E

BPC-157 + TB-500 (Wolverine Stack) 20 mg Factory batch COA protected preview

BPC-157 + TB-500 (Wolverine Stack)20 mg · WHJLP-BB20-260330-E

BPC-157 + TB-500 (Wolverine Stack) 30 mg Factory batch COA protected preview

BPC-157 + TB-500 (Wolverine Stack)30 mg · WHJLP-BB30-260330-E

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require component-specific exact sequence, termini, salt/counterion, theoretical and observed high-resolution intact mass, sequence evidence, stability-indicating chromatographic purity, quantitative peptide content, water, counterion and residual solvents
If co-presented, also require methods that resolve both components and relevant impurities, ratio and content-uniformity results, mixture-specific stability and container-closure evidence
Sterility and bacterial endotoxin are separate released attributes; appearance or a blended HPLC percentage is insufficient.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

BPCTB-10MG10 mg10 vials

BPCTB-20MG20 mg10 vials

BPCTB-30MG30 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Use only the released-lot COA, SDS and stability statement for the actual presentation. If separate, qualify each component independently; if co-presented, require mixture-specific stability, compatibility, concentration, matrix, container and hold-time evidence. Do not apply a generic 2–8°C or 30-day rule.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity: PubChem CID 9941957 for BPC-157 and PubChem CID 62707662 for N-acetylated Ac-LKKTETQ. Evidence boundary: Lee and Padgett 2021, PMID 34324435, was a small uncontrolled retrospective report; its combination arm was described as BPC-157 plus thymosin beta-4/TB4 and did not establish sequence-resolved Ac-LKKTETQ. Pharmacokinetic context: Frontiers in Pharmacology 2022, PMCID PMC9794587, reports animal BPC-157 values only. Regulatory context: FDA's current compounding-safety page, staff briefing materials for the scheduled July 23–24, 2026 PCAC meeting and the official 2026 WADA Prohibited List. None of these sources validates the marketed two-peptide pairing.

01
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
Current Reviews in Musculoskeletal Medicine · 2025 · narrative review (peer-reviewed)
Open source
02
Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
Biomedicines · 2021 · peer-reviewed original research (animal model)
Open source
03
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Journal of Applied Physiology · 2011 · peer-reviewed original research (animal model)
Open source
04
Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds
Regulatory Toxicology and Pharmacology · 2020 · peer-reviewed original research (preclinical toxicology)
Open source
05
Thymosin beta4 accelerates wound healing
Journal of Investigative Dermatology · 1999 · peer-reviewed original research (foundational/landmark)
Open source
06
Progress on the Function and Application of Thymosin β4
Frontiers in Endocrinology · 2021 · peer-reviewed review
Open source
07
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry
Journal of Chromatography A · 2012 · peer-reviewed original research (analytical/regulatory)
Open source
08
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Alternative Therapies in Health and Medicine · 2021 · peer-reviewed retrospective chart review (small, uncontrolled)
Open source

Product FAQ

Questions buyers ask about BPC-157 + TB-500 (Wolverine Stack)

Does separate evidence for BPC-157 and TB-500 prove synergy of the pairing?+

No. BPC-157 and the Ac-LKKTETQ TB-500 fragment have different proposed biology, but no identified controlled peer-reviewed study established additive efficacy, synergy, compatibility or safety for the marketed pairing. The small retrospective knee report described its combination material only as thymosin beta-4/TB4 and did not establish a sequence-resolved Ac-LKKTETQ 7-mer; it therefore cannot validate this material. Combination hypotheses require direct controls against each component and the vehicle.

Does a variant label prove that the two peptides are co-lyophilized at the stated ratio?+

No. Nominal labels such as 5 mg + 5 mg describe requested component amounts but do not prove physical presentation, actual content, uniformity or stability. The quote, container record and released-lot COA must state whether components are separate or co-presented, the content acceptance range for each component, blend or fill-uniformity evidence and the test method.

Which analytical controls are required for a two-peptide material?+

Require each component’s exact sequence, termini, salt/counterion, theoretical and observed intact mass, sequence evidence, stability-indicating chromatography and quantitative peptide content. For co-presented material, methods must also resolve both components and relevant impurities, verify ratio and content uniformity, and support mixture-specific stability. A generic HPLC area percentage or a single mass trace cannot qualify both peptides.

BPC-157 + TB-500 (Wolverine Stack)

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about BPC-157 + TB-500 (Wolverine Stack)

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

BPC-157 + TB-500 (Wolverine Stack) factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing

Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration

Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds

Thymosin beta4 accelerates wound healing

Progress on the Function and Application of Thymosin β4

Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry

Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

Questions buyers ask about BPC-157 + TB-500 (Wolverine Stack)

Compare adjacent molecules and documentation needs.

BPC-157

TB-500

GHK-Cu

TB500 Fragment (Frag 17-23)